{"id":94009,"date":"2025-10-23T20:33:11","date_gmt":"2025-10-23T20:33:11","guid":{"rendered":"https:\/\/www.newsbeep.com\/il\/94009\/"},"modified":"2025-10-23T20:33:11","modified_gmt":"2025-10-23T20:33:11","slug":"with-60000-members-shemed-raises-e43-million-to-advance-personalised-womens-healthcare-in-the-uk","status":"publish","type":"post","link":"https:\/\/www.newsbeep.com\/il\/94009\/","title":{"rendered":"With 60,000+ members, SheMed raises \u20ac43 million to advance personalised women\u2019s healthcare in the UK"},"content":{"rendered":"<p><a href=\"https:\/\/www.shemed.co.uk\" target=\"_blank\" rel=\"noopener nofollow\">SheMed<\/a>, London\u2019s female-founded HealthTech company changing how women access personalised healthcare, today announced it has raised \u20ac43 million to further develop its innovative health platform and advance new breakthroughs for preemptive healthcare.<\/p>\n<p>The new funding will be used to expand SheMed\u2019s UK operations, scaling its medical and technology teams, strengthening clinical infrastructure and enhancing its data-driven capabilities.<\/p>\n<p>\u201cFor more than a decade, I searched for answers to an undiagnosed health issue,\u201d said Olivia Ferro, Co-founder and CEO of SheMed. \u201cAs a GLP-1 patient myself, I know how transformative the right diagnosis and treatment can be. We built SheMed to give women the personalised support I struggled to find: care that listens, understands and empowers.\u201d<\/p>\n<p data-start=\"0\" data-end=\"1319\">The new \u00a0funding for SheMed fits within a broader wave of 2025 investment activity in UK and European HealthTech, particularly in preventative care and women\u2019s health.<\/p>\n<p data-start=\"0\" data-end=\"1319\">Other UK companies in adjacent areas have also attracted significant capital this year \u2013 including <a class=\"decorated-link\" href=\"https:\/\/www.eu-startups.com\/2025\/07\/london-based-numan-raises-e51-6-million-for-the-next-era-of-preventative-digital-healthcare\/\" target=\"_new\" rel=\"noopener nofollow\" data-start=\"318\" data-end=\"482\">Numan<\/a>, which secured \u20ac51.6 million to expand its digital healthcare platform into female health, and <a class=\"decorated-link\" href=\"https:\/\/www.eu-startups.com\/2025\/05\/hormona-a-healthtech-startup-enabling-women-to-track-understand-and-optimise-their-hormones-raises-e7-8-million\/\" rel=\"noopener nofollow\" data-start=\"582\" data-end=\"768\" target=\"_blank\">Hormona<\/a>, which raised \u20ac7.8 million for its AI-driven hormone health tracking solution.<\/p>\n<p data-start=\"0\" data-end=\"1319\">Related UK-based ventures such as <a class=\"decorated-link\" href=\"https:\/\/www.eu-startups.com\/2025\/06\/london-based-scale-up-perci-health-raises-e4-million-to-scale-ai-driven-virtual-cancer-clinic\/\" rel=\"noopener nofollow\" data-start=\"886\" data-end=\"1059\" target=\"_blank\">Perci Health<\/a> and <a class=\"decorated-link\" href=\"https:\/\/www.eu-startups.com\/2025\/10\/no-drill-required-londons-comind-raises-e85-million-to-replace-invasive-brain-monitoring\/\" target=\"_new\" rel=\"noopener nofollow\" data-start=\"1064\" data-end=\"1226\">CoMind<\/a> have also secured fresh capital to advance personalised and data-led healthcare solutions.<\/p>\n<p data-start=\"1321\" data-end=\"1891\" data-is-last-node=\"\" data-is-only-node=\"\">According to <a class=\"decorated-link\" href=\"https:\/\/www.eu-startups.com\/2025\/10\/inside-the-uks-innovation-surge-record-spinout-funding-ai-initiatives-and-academic-momentum\/\" target=\"_new\" rel=\"noopener nofollow\" data-start=\"1334\" data-end=\"1514\">EU-Startups\u2019 analysis<\/a>, UK startups collectively raised around \u20ac14.7 billion in 2025 to date, signalling sustained investor confidence in the country\u2019s innovation ecosystem.<\/p>\n<p data-start=\"1321\" data-end=\"1891\" data-is-last-node=\"\" data-is-only-node=\"\">Within this context, SheMed\u2019s new funding reflects both a strong national momentum and the growing investor recognition of women\u2019s health and metabolic-care platforms as key growth areas in European healthcare innovation.<\/p>\n<p>\u201cThe demand for SheMed\u2019s services has been extraordinary,\u201d added Chloe Ferro, Co-founder and President of SheMed. \u201cWomen are seeking care that recognises their individuality, their biology and their experiences. It\u2019s why women continue to turn to SheMed for a tailored, more supportive path to healthcare.\u201d<\/p>\n<p>Founded in April 2024 by sisters Olivia and Chloe Ferro, SheMed has grown rapidly to a market frontrunner for its ability to address the persistent gap in women\u2019s healthcare: access to customised, trustworthy and sustainable solutions.<\/p>\n<p>Its programme integrates medical oversight, wellness tracking and 24\/7 support through an all-in-one digital platform, ensuring every woman receives tailored individual care while providing a platform that is redefining the healthcare space.<\/p>\n<p>The new investment will also support new research and patient-experience initiatives designed to improve access to high-quality, personalised care for women across the UK.<\/p>\n<p>SheMed is most known for its leading GLP-1 and weight-management platform, which blends medical expertise, data insights and continuous support to help women achieve lasting health results.<\/p>\n<p>In less than a year, SheMed has cared for 60k+ members, reportedly cementing its position as the fastest growing GLP-1 programme in the UK.<\/p>\n<p>Later this month, SheMed will publish results from the first-ever female-focused GLP-1 clinical study, marking a significant milestone in women\u2019s metabolic-health research. The findings will provide insights into how GLP-1 medications affect women\u2019s hormonal and metabolic responses, helping refine future treatment pathways.<\/p>\n","protected":false},"excerpt":{"rendered":"SheMed, London\u2019s female-founded HealthTech company changing how women access personalised healthcare, today announced it has raised \u20ac43 million&hellip;\n","protected":false},"author":2,"featured_media":94010,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[34],"tags":[62975,62976,60918,4569,163,521,20473,62977,85,46,442,62978,62979,62980,62981,2985],"class_list":{"0":"post-94009","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-healthcare","8":"tag-chloe-ferro","9":"tag-comind","10":"tag-femtech","11":"tag-glp-1","12":"tag-health","13":"tag-healthcare","14":"tag-healthtech","15":"tag-hormona","16":"tag-il","17":"tag-israel","18":"tag-london","19":"tag-numan","20":"tag-olivia-ferrero","21":"tag-perci-health","22":"tag-shemed","23":"tag-weight-management"},"_links":{"self":[{"href":"https:\/\/www.newsbeep.com\/il\/wp-json\/wp\/v2\/posts\/94009","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.newsbeep.com\/il\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.newsbeep.com\/il\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/il\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/il\/wp-json\/wp\/v2\/comments?post=94009"}],"version-history":[{"count":0,"href":"https:\/\/www.newsbeep.com\/il\/wp-json\/wp\/v2\/posts\/94009\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/il\/wp-json\/wp\/v2\/media\/94010"}],"wp:attachment":[{"href":"https:\/\/www.newsbeep.com\/il\/wp-json\/wp\/v2\/media?parent=94009"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.newsbeep.com\/il\/wp-json\/wp\/v2\/categories?post=94009"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.newsbeep.com\/il\/wp-json\/wp\/v2\/tags?post=94009"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}